Introduction
============

Over the past decade, the understanding of human cancer and development of molecular targeted therapies have benefitted from genomic technologies ([@b1-etm-0-0-5533]). A large proportion of patients with cancer suffer adverse effects from molecular targeted or cytotoxic agents while exhibiting no effective response in terms of tumor shrinkage ([@b2-etm-0-0-5533]). Although molecular targeted therapy is a standard cancer treatment, anticancer therapies using cytotoxic drugs remain a gold standard approach for cancer treatment ([@b3-etm-0-0-5533]--[@b5-etm-0-0-5533]). The efficacy of cytotoxic anticancer drugs varies among individual patients ([@b6-etm-0-0-5533]--[@b8-etm-0-0-5533]). Although a number of recent studies have attempted to establish a diagnostic method for predicting chemosensitivity ([@b9-etm-0-0-5533]--[@b12-etm-0-0-5533]), to the best of our knowledge, no clinically applicable genetic markers for the prediction of sensitivity or resistance to cytotoxic anticancer drugs have been developed. In order to distinguish which patients may respond to certain drugs from those who may not, prior to initiating treatment, to offer a 'cancer precision medicine' program of more effective chemotherapy and also to relieve patients from severe adverse events, a larger set of genetic variants in tumors must be identified to serve as accurate predictive markers for each anticancer drug.

The development of next generation sequencing technologies has revolutionized cancer genomic research because it provides a comprehensive method of detecting genomic alterations (somatic mutations) in cancer cells ([@b13-etm-0-0-5533]--[@b15-etm-0-0-5533]). A number of studies have reported an association between clinical outcomes and variant allele frequencies (VAFs) in tumors ([@b16-etm-0-0-5533]--[@b20-etm-0-0-5533]). As the properties of cancer cells may be influenced by complicated interactions among genes associated with cancer, such as oncogenes or tumor suppressor genes expressed in cancer cells ([@b21-etm-0-0-5533]--[@b23-etm-0-0-5533]), the present study hypothesized that the genetic variants of these genes within the tumors may serve important roles in determining the response to cytotoxic anticancer drugs.

In the current study, to identify genetic markers for sensitivity or resistance to 9 cytotoxic anticancer drugs, all exons of 409 genes associated with cancer from 79 cancer xenografts in mice that had been established from 12 different human organs were sequenced. The association between single nucleotide variants (SNVs) detected in the xenografts and sensitivities to the 9 cytotoxic anticancer drugs were then investigated using a nonparametric approach. The present study identifies the genes associated with cancer that may also be associated with sensitivity to ≥1 of the 9 anticancer drugs examined. The results of the current study may help to elucidate the mechanism that causes the different clinical responses to chemotherapy among patients and may be applicable in the development of a prediction system to optimize treatment.

Materials and methods
=====================

### Xenografts, anticancer drugs and examination of xenografts for sensitivity to anticancer drugs

A total of 79 human cancer xenografts, including 12 breast cancers, 12 gastric cancers, 10 neuroblastomas, 10 non-small-cell lung cancers, 7 gliomas, 6 pancreatic cancers, 5 colon cancers, 5 choriocarcinomas, 4 small-cell lung cancers, 4 hematopoietic cancers, 3 ovarian cancers and 1 osteosarcoma were transplanted to athymic BALB/c-*nu*/*nu* mice (weight, 26.3±1.8 g; age, 8--10 weeks) and maintained by serial subcutaneous transplantation of 2×2×2 mm fragments into the flank once a month as described previously ([@b24-etm-0-0-5533]). A total of 7,900 mice were purchased from Japan CLEA Inc. (Tokyo, Japan) and housed in a controlled temperature of 23±1°C and relative humidity 50--70%, with *ad libitum* access to food and water. Mice were divided into 10 groups of 6 mice, per xenograft. A total of 79 human tumor tissues from 79 patients were obtained aseptically during surgery or autopsy at 13 hospitals. Mitomycin C (MMC), adriamycin (ADR; both Kyowa Hakko Bio Co., Ltd., Tokyo, Japan), cyclophosphamide (CPM), vincristine (VCR), vinblastine (VLB; all Shionogi & Co. Ltd., Osaka, Japan), nimustine (ACNU; Daiichi Sankyo Co., Ltd., Tokyo, Japan), cisplatin (DDP), 5-fluorouracil (5FU; both Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) and methotrexate (MTX; Wyeth Lederle Japan, Ltd., Tokyo, Japan) were dissolved in sterile 0.85% NaCl containing 1% mannitol (Wako Pure Chemical Industries, Ltd., Osaka, Japan). The maximum tolerated dose for these drugs in mice was determined as described previously \[MMC: 6.7 mg/kg, CPM: 260 mg/kg, ACNU: 48 mg/kg, DDP: 10 mg/kg, ADR: 12 mg/kg, VCR: 1.6 mg/kg, VLB: 11 mg/kg, 5-FU: 19 mg/kg (×5), MTX: 15 mg/kg (×5)\] ([@b24-etm-0-0-5533]). Each anticancer drug was administered individually, at the maximum tolerated dose, to nude mice bearing human cancer xenografts (in groups of 6). Administration route was intravenous infusion in all cases. 5-FU and MTX were administered for 5 days and all other drugs in a single dose. The control group did not receive any treatment (6 mice per xenograft). Chemosensitivity was calculated as the relative tumor volume of treated mice (T) with respect to control (C) using the mean values for the treatment and control groups on day 14, as described previously \[T/C (%)\] ([@b25-etm-0-0-5533],[@b26-etm-0-0-5533]). All animal studies were approved by the institutional committee of Central Institute for Experimental Animals, and conducted according to previously described protocols ([@b27-etm-0-0-5533]). Mice were sacrificed 21 days after drug administration.

### Gene expression analysis

Total RNA was extracted from xenograft untreated tissues using ISOGEN (Nippon Gene Co., Ltd., Toyama, Japan) according to the manufacturer\'s protocol. To eliminate genomic DNA contamination, samples were treated with Recombinant DNase (RNase-free; Takara Bio, Inc., Otsu, Japan) following the manufacturer\'s protocol. cDNA was prepared from 5 µg total RNA using SuperScript III reverse transcriptase (Thermo Fisher Scientific, Inc., Waltham, MA, USA). Firstly, 5 µg total RNA, 1 µl oligo dT primers (Invitrogen; Thermo Fisher Scientific, Inc.) and diethyl pyrocarbonate (DEPC) water were mixed to a total volume of 16 µl. This mixture was incubated at 70°C for 10 min and then chilled on ice for 5 min. The following components were added: 5 µl 5X first strand buffer (Invitrogen; Thermo Fisher Scientific, Inc.), 1 µl 25 mM dNTP (Wako Pure Chemical Industries, Ltd.), 2.5 µl 100 mM DTT (Invitrogen; Thermo Fisher Scientific, Inc.) and 0.5 µl Recombinant RNase Inhibitor (Takara Bio, Inc.), followed by 1.5 µl SuperScript III Reverse Transcriptase. This reaction mixture was incubated at 42°C for 50 min and terminated by heating to 70°C for 15 min. The cDNA products were stored at −20°C until required. mRNA expression profiles were obtained from an in-house cDNA microarray consisting of 23,040 genes, as described previously ([@b25-etm-0-0-5533],[@b26-etm-0-0-5533]). For the 69 genes ([Table I](#tI-etm-0-0-5533){ref-type="table"}) whose expression was not available in the aforementioned profile, reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was completed, using the SYBR Green Real-Time PCR system (Thermo Fisher Scientific, Inc.) and the StepOnePlus and 7900HT Fast Real-time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.), following the manufacturer\'s protocols. Each PCR reaction mixture contained 5 µl Fast SYBR Green Master Mix (2x) (Applied Biosystems; Thermo Fisher Scientific, Inc.), 0.2 µl of each primer (10 pmol/µl) (Sigma-Aldrich; Merck KGaA), 1 µl cDNA and DEPC water (Ambion; Thermo Fisher Scientific, Inc.), for a total volume of 10 µl. The reaction was performed at 95°C for 20 sec, 40 cycles of 95°C for 3 sec and 60°C for 30 sec, 95°C for 15 sec, 60°C for 1 min and 95°C for 15 sec. The sequences of the primers are shown in [Table I](#tI-etm-0-0-5533){ref-type="table"}. The level of mRNA was assessed using the relative standard curve method, relative to β-actin reference gene ([@b28-etm-0-0-5533]).

### Sample preparation and targeted next-generation sequencing

Tumor genomic DNA was extracted from 79 xenografts using the QIAmp DNA Mini kit (QIAGEN, Hilden, Germany) according to the manufacturer\'s protocol. In the screening study, targeted next generation sequencing was performed in 59 xenografts (12 breast cancers, 12 gastric cancers, 10 neuroblastomas, 10 non-small-cell lung cancers, 7 gliomas, 6 pancreatic cancers, 1 ovarian cancer and 1 osteosarcoma) using the Ion AmpliSeq Comprehensive Cancer Panel (CCP; Thermo Fisher Scientific, Inc.), which targets the exons of 409 tumor suppressor genes and frequently cited and mutated oncogenes. DNA concentrations were determined using the TaqMan RNase P Detection Reagents kit (Thermo Fisher Scientific, Inc.). Barcoded amplicon libraries for individual DNA samples were prepared using the Ion Xpress Barcode Adapters and the Ion AmpliSeq Library kit 2.0 (Thermo Fisher Scientific, Inc.) following the manufacturer\'s protocol. Pooled barcoded libraries were subsequently conjugated with sequencing beads by emulsion PCR and enriched using the Ion PI Hi-Q Chef kit and Ion Chef (Thermo Fisher Scientific, Inc.) according to the Ion Torrent protocol (Thermo Fisher Scientific, Inc.). Sequencing of templates was performed with 8--10 samples per Ion PI Chip V3 using the Ion Proton system (Thermo Fisher Scientific, Inc.), according to the manufacturer\'s protocols. Sequencing reads generated were aligned with the human genome build 19 (hg19) and mouse genome build 38 (mm10). Reads with an alignment score where mm10 ≥hg19 were considered as reads derived from the mouse genome and subsequently removed. The Variant Caller plugin (version 5.0.2.1; Thermo Fisher Scientific, Inc.) was used to identify variations from the reference sequence (hg19). In the replication study, targeted sequencing was performed in 20 xenografts, including 5 colon cancers, 5 choriocarcinomas, 4 small-cell lung cancers, 4 hematopoietic cancers and 2 ovarian cancers. PolyPhen2 ([genetics.bwh.harvard.edu/pph2/](genetics.bwh.harvard.edu/pph2/)) and SIFT ([sift.jcvi.org/](sift.jcvi.org/)) were used for the computational prediction of the functional changes that amino acid substitutions may have on protein function. Variants were predicted to be 'benign', 'possibly damaging' or 'probably damaging' by Polyphen2, and 'tolerated' or 'damaging' by SIFT.

### Statistical analysis

Xenografts were classified into three groups according to variant allele frequencies (VAFs), low (\<10%), middle (10--90%) and high (\>90%), and the difference of sensitivity to each anticancer drug (T/C (%)) among the groups was examined using a nonparametric approach (Mann-Whitney U-test for two groups or Kruskal-Wallis test for three groups). To identify genes, which may distinguish patients who may respond to the anticancer drugs, from those who may not, SNVs of which the difference between the maximum and the minimum VAF was \<50% were removed from further analysis. P\<8.39×10^−5^ (0.05/596) was determined to indicate a statistically significant difference in the replication study for the adjustment of multiple testing by the strict Bonferroni correction. A Pearson correlation coefficient was performed to estimate the association between the gene expression and sensitivity to each anticancer drug. Combination effects were investigated by totaling the score of each VAF group.

Results
=======

### Identification of the candidate SNVs associated with chemosensitivity

To identify genetic variants significantly associated with the efficacy of one or more of nine anticancer drugs (5FU, ACNU, ADR, CPM, DDP, MMC, MTX, VCR and VLB) examined in the current nude mice system, all exons of 409 genes associated with cancer using 59 xenografts derived from breast cancer, gastric cancer, neuroblastoma, non-small-cell lung cancer, glioma, pancreatic cancer, ovarian cancer and osteosarcoma at the screening stage were sequenced. A total of 5,494 SNVs were identified in the sequence analysis of the 59 xenografts, and the median number of SNVs called in one sample was 988. A total of 2,206 SNVs with a difference between the maximum and the minimum VAF \<50% were removed from further analysis, and 2,087, 2,134, 2,134, 2,134, 2,134, 2,134, 1,944, 2,124 and 2,124 SNVs were assessed for sensitivity to 5FU, ACNU, ADR, CPM, DDP, MMC, MTX, VCR and VLB, respectively. The xenografts were classified into three groups, low (\<10%), middle (10--90%) and high (\>90%) VAF, and the association between the VAF group and sensitivities to cytotoxic anticancer drugs was assessed using the Kruskal-Wallis test or Mann-Whitney U-test. Chemosensitivity was calculated as T/C and the variants whose allele frequency was higher in xenografts with lower T/C as were defined as 'chemosensitive variants' and variants whose allele frequency were higher in xenografts with higher T/C as 'chemoresistant variants'. As presented in [Table II](#tII-etm-0-0-5533){ref-type="table"}, when 59 xenografts were analyzed in a screening study, 43--98 SNVs exhibited a potential association with sensitivity to the aforementioned 9 drugs. The top 10 variants that revealed the smallest P-values are displayed in [Tables III](#tIII-etm-0-0-5533){ref-type="table"}--[XI](#tXI-etm-0-0-5533){ref-type="table"}.

In the screening study using 59 xenografts, three SNVs were observed to exhibit associations (P\<0.001) with the associated genes; rs1805321 (P=0.00018; [Table X](#tX-etm-0-0-5533){ref-type="table"}) and rs62456182 (P=0.00054; [Table X](#tX-etm-0-0-5533){ref-type="table"}) in PMS1 Homolog 2, Mismatch Repair System Component, and rs13382825 (P=0.00092; [Table VIII](#tVIII-etm-0-0-5533){ref-type="table"}) in LDL Receptor Related Protein 1B. The three SNVs were associated with sensitivity to MMC and VCR (no. 1 and 2 in [Table X](#tX-etm-0-0-5533){ref-type="table"}), respectively ([Tables VIII](#tVIII-etm-0-0-5533){ref-type="table"} and [X](#tX-etm-0-0-5533){ref-type="table"}). The xenografts with higher VAFs of rs1805321 and rs62456182 demonstrated an increased response to VCR compared with those that exhibited a lower variant allele frequency of the two SNVs ([Table X](#tX-etm-0-0-5533){ref-type="table"}). By contrast, xenografts with higher VAFs of rs13382825 exhibited a decreased response to MMC compared with those that presented with lower variant allele frequencies ([Table VIII](#tVIII-etm-0-0-5533){ref-type="table"}), suggesting that this genetic variant is associated with resistance to MMC.

### Replication study using additional xenografts

To further validate the result of the screening-stage analysis, a replication study was performed, using 596 SNVs showing P\<0.05 in ≥1 anticancer drugs in the screening set using independent samples of 20 xenografts. No SNVs revealed significant levels of association in the replication study following Bonferroni correction, including rs1805321, rs62456182 and rs13382825, which demonstrated an association (P\<0.001) with VCR (no. 1 and 2; [Table X](#tX-etm-0-0-5533){ref-type="table"}) and MMC (no. 1; [Table VIII](#tVIII-etm-0-0-5533){ref-type="table"}) in the screening study.

A combined result of the screening and replication studies suggested potential associations of 35 SNVs, which exhibited a stronger association in the combined study than those in screening study, with sensitivity to ≥1 anticancer drugs ([Table XII](#tXII-etm-0-0-5533){ref-type="table"}). However, significant association was not observed in these SNVs (0.0011\<P~combined~\<0.035 in [Table XII](#tXII-etm-0-0-5533){ref-type="table"}) following Bonferroni correction. The SNV which revealed the lowest P-value in the combined study was rs79555258 (no. 1 in [Table XII](#tXII-etm-0-0-5533){ref-type="table"}) in Activin A Receptor Type 2A (*ACVR2A;* P=0.0011). As presented in [Fig. 1](#f1-etm-0-0-5533){ref-type="fig"}, xenografts with more variant alleles of rs79555258 in the three studies (screening, replication and combined) exhibited a lower response to CPM than those with less variant alleles, suggesting that this variant may be associated with resistance to CPM.

### Identification of SNVs associated with multi-drug sensitivity

Of the 35 SNVs, that demonstrated a potential association with sensitivity to ≥1 anticancer drugs examined, rs16903989 and rs201432181 (no. 16 and 3, respectively; [Table XII](#tXII-etm-0-0-5533){ref-type="table"}) were commonly associated with sensitivity to 2 (VCR and CPM) and 4 (ACNU, MMC, VLB and ADR) drugs, respectively. Xenografts with more variant alleles in rs16903989, which is located in intron 9 of Leukemia Inhibitory Factor Receptor Alpha (*LIFR*), exhibited a higher response to VCR and CPM (P~combined~=0.0098 and 0.026, respectively; [Table XII](#tXII-etm-0-0-5533){ref-type="table"}). The correlation analysis between gene expression and drug sensitivity demonstrated a significantly positive correlation between the expression level of *LIFR* and sensitivity to VCR (*r*=0.42, P=0.00031) and CPM (*r*=0.36, P=0.0020) as presented in [Table XII](#tXII-etm-0-0-5533){ref-type="table"} (no. 16). The xenografts with more variant alleles in rs201432181, which is located in exon 19 of *GPR124*, demonstrated a higher response to ACNU, MMC, VLB and ADR (P~combined~=0.0013, 0.0040, 0.017 and 0.029, respectively; no. 3 [Table XII](#tXII-etm-0-0-5533){ref-type="table"}), however, no significant association was observed between the expression level of *GPR124* and sensitivity to these 4 cytotoxic anticancer drugs in the present study (ACNU, MMC, VLB and ADR; [Table XII](#tXII-etm-0-0-5533){ref-type="table"}).

### Combination analysis with markedly associated SNVs with chemosensitivity

A combined effect of markedly associated SNVs with chemosensitivity was investigated (P~combined~\<0.01) on sensitivities to ADR, 5FU, ACNU and CPM ([Table XII](#tXII-etm-0-0-5533){ref-type="table"}). The xenografts were scored 0, 1 and 2 based on the allele frequency of the chemosensitive variants (P~combined~\<0.01) as low (\<10%), middle (10--90%), and high (\>90%), respectively. Furthermore, the xenografts were scored 2, 1 and 0 depending on the allele frequency of the chemoresistant variants (P~combined~\<0.01) as low (\<10%), middle (10--90%), and high (\>90%), respectively. The xenografts were then classified into 4--6 groups according to the sum of the scores. The combination analysis using rs4589708, rs113962761 and rs1050171 revealed a cumulative effect on sensitivity to ADR (P=0.000012; [Fig. 2](#f2-etm-0-0-5533){ref-type="fig"}). Similarly, combination analysis using strongly associated SNVs with sensitivity to 5FU, ACNU and CPM (P\<0.01), also revealed a cumulative effect on sensitivity to them (P=0.00025, P=0.000076 and P=0.00021, respectively, data not shown).

Discussion
==========

The present study conducted two-step association studies between frequencies of SNVs in 409 genes (three VAF groups; \<10%, 10--90%, \>90%) and the sensitivities to 9 cytotoxic anticancer drugs using 79 human cancer xenografts, and identified 35 SNVs with potential associations to sensitivity or resistance to ≥1 cytotoxic anticancer drugs in a combined study. The SNV demonstrating the lowest P-value in the combined study, rs79555258, is located in intron 9 of the *ACVR2A* gene, and tumors with more variant alleles of rs79555258 were demonstrated to be more likely to be resistant to CPM. *ACVR2A* is a receptor for activin A, which is a member of the transforming growth factor-β superfamily of cytokines and a putative tumor suppressor gene that is frequently mutated in microsatellite-unstable colon cancer ([@b29-etm-0-0-5533],[@b30-etm-0-0-5533]). Activin participates in the regulation of cell proliferation, differentiation and migration, DNA damage repair and apoptosis ([@b29-etm-0-0-5533],[@b31-etm-0-0-5533]--[@b33-etm-0-0-5533]). Although the functional relevance of *ACVR2A* to the sensitivity to CPM remains to be elucidated, the single nucleotide variant (rs79555258) of this gene may be a predictive marker for sensitivity to CPM.

rs16903989, which was located in intron 9 of the *LIFR* gene was commonly associated with sensitivity to CPM and VCR. *LIFR* forms a heterodimer with a signal transducer, gp130 and leads to activation of the Janus kinase/signal transducer and activator of transcription and mitogen activated protein kinase cascades ([@b34-etm-0-0-5533]). *LIFR* has been demonstrated to be downregulated in breast cancer and was identified as a metastasis suppressor ([@b35-etm-0-0-5533],[@b36-etm-0-0-5533]). A single nucleotide polymorphism in *LIFR* (rs3729740) was reported to be a potential predictive marker for sensitivity to a molecular-targeted drug, cetuximab ([@b37-etm-0-0-5533]). Furthermore, the expression level of *LIFR* was revealed to be associated with sensitivity to VCR in glioblastoma cells ([@b38-etm-0-0-5533]), and the data of the current study also indicated a positive correlation between the expression level of *LIFR* and sensitivity to VCR. Although the role of *LIFR* in response to anticancer therapy has not yet been clarified, this gene may be associated with a common mechanism of drug response. The current study also demonstrated that rs201432181 in *GPR124* was typically associated with sensitivity to 4 anticancer drugs (ACNU, ADR, MMC and VLB). rs201432181 is a nonsynonymous substitution (p.D1313 V), and the effect of the substitution on protein function was predicted to be 'possibly damaging' by Polyphen2. *GPR124* is known to regulate vascular endothelial growth factor-induced tumor angiogenesis *in vitro* ([@b39-etm-0-0-5533]). Therefore, the promotion of tumor angiogenesis by activation of pathway involved with *GPR124* may enhance the delivery of anticancer drugs.

To investigate the tissue specificity of the chemosensitivity-related SNVs identified in the current study, subgroup analysis for breast and gastric cancer xenografts was performed as they included the largest number of tissues (n=12 each) used in the present study. SNVs that were commonly associated with chemosensitivity in the xenografts derived from breast and gastric cancer were identified (rs79555258 for CPM, P=0.031 and 0.086, respectively). By contrast, the study also observed the SNVs associated with chemosensitivity in the xenografts derived from breast cancer, but not in those from gastric cancer.

Of the 409 genes sequenced using CCP in the current study, Excision Repair Cross-Complementation Group 1, Excision Repair Cross-Complementation Group 2, *AKT1* and Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit α have previously been reported to be candidates or promising predictors for sensitivity to cisplatin ([@b40-etm-0-0-5533]--[@b42-etm-0-0-5533]). However, no SNVs associated with these genes demonstrated a significant association with cisplatin in the current study, this is potentially because the sample size was too small. Further studies using a large number of xenografts and clinical samples are required to confirm whether they may be a predictive marker for sensitivity to cisplatin clinically.

In conclusion, the present study used 79 human cancer xenografts implanted into nude mice to identify 35 possible genetic variants associated with the sensitivity or resistance to ≥1 anticancer drugs from a total of 9. These findings provide novel insights into personalized selection of chemotherapy for patients with cancer, however; further functional analysis is required to verify the results of the current study and to clarify their biological mechanisms, which have effects on the clinical outcomes of patients receiving the chemotherapy. Accumulation of data is expected to lead to 'cancer precision medicine' using more effective and less harmful anticancer drugs.
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![Association between rs79555258 and sensitivity to CPM. The xenografts with higher variant allele frequency in rs79555258 exhibited a lower response to CPM compared with those that presented with a lower variant allele frequency. The (A) screening study, (B) replication study and (C) combined study are presented where the sensitivity to CPM is represented by relative tumor volume of T with respect to C. 'x' represents a single xenograft. Boxes represent the interquartile range (IQR) between first and third quartiles and the line inside represents the median. The whiskers outside the box extend to the highest and lowest value within 1.5 times the IQR. CPM, cyclophosphamide; T, treated mice; C, control.](etm-15-02-1339-g00){#f1-etm-0-0-5533}

![Combined effects of rs4589708, rs113962761 and rs1050171 on sensitivity to ADR. The distribution of ADR sensitivity is presented in the four score groups. The xenografts were classified into four groups based on the sum of the score given to each variant allele frequencies group for the three single nucleotide variants. 'x' represents a single xenograft. Boxes represent the interquartile range (IQR) between first and third quartiles and the line inside represents the median. The whiskers outside the box extend to the highest and lowest value within 1.5 times the IQR. ADR, Adriamycin; T, treated mice; C, control.](etm-15-02-1339-g01){#f2-etm-0-0-5533}

###### 

Sequences of primers used for qRT-PCR.

  Gene         Primer sequence
  ------------ ---------------------------------------
  *MTRR*       Forward 5′-AGCCTACTCCAAAGACTGCA-3′
               Reverse 5′-CAGGTATATGCTGGGGTAAGGT-3′
  *ADAMTS20*   Forward 5′-GGAAATTACTGTGTGGGCCG-3′
               Reverse 5′-GCACTGCTTCTCTCGAAAGT-3′
  *ASXL1*      Forward 5′-TTCACGCTCAAGAAGGATGC-3′
               Reverse 5′-GGCTTCATTAGACCCACAGC-3′
  *ADGRA2/*    Forward 5′-AGAAGGTGGAGATCGTGGTG-3′
  *GPR124*     Reverse 5′-AGGACTGGTAGGCTGTGATG-3′
  *ADGRB3/*    Forward 5′-AACGGGCGAAGAAGTGAGAA-3′
  *BAI3*       Reverse 5′-GTGGCATTCAGGGGACATTG-3′
  *AKT1*       Forward 5′-TCAACAACTTCTCTGTGGCG-3′
               Reverse 5′-GAAGGTGCGTTCGATGACAG-3′
  *AMER1/*     Forward 5′-GGGTATCTGTACTCTGCCTAGTT-3′
  *FAM123B*    Reverse 5′-CTTGCTGAGACCTTTCTTGGAG-3′
  *ATR*        Forward 5′-TGTAAATGTGAGTGGAAGCCA-3′
               Reverse 5′-AATGACAGGAGGGAGTTGCT-3′
  *BCL3*       Forward 5′-AACCTGCCTACACCCCTATAC-3′
               Reverse 5′-CACCACAGCAATATGGAGAGG-3′
  *BCL6*       Forward 5′-ACGGCTATGTACCTGCAGAT-3′
               Reverse 5′-TCTTCACGAGGAGGCTTGAT-3′
  *BRIP1/*     Forward 5′-CCACTCTGGCTGCAAAGTTA-3′
  *FANCJ*      Reverse 5′-TCTGTTCCAAAGCAATGACGT-3′
  *CDH1*       Forward 5′-ATTTTTCCCTCGACACCCGAT-3′
               Reverse 5′-TCCCAGGCGTAGACCAAGA-3′
  *CRBN*       Forward 5′-TCCTTGAGCTAAGAACACAGTCA-3′
               Reverse 5′-AAGGCAACACACATTCGGGAA-3′
  *CRTC1*      Forward 5′-GGTCCCCGGAATCAACATCT-3′
               Reverse 5′-AGTGGATGTTGGTCAGGTCG-3′
  *CDKN2A*     Forward 5′-CCTCAGACATCCCCGATTGA-3′
               Reverse 5′-GAAAGCGGGGTGGGTTGT-3′
  *CMPK1*      Forward 5′-ATGGATGGGAAGGCAGATGT-3′
               Reverse 5′-TCCAAGCTCTCTCTGTTGTCA-3′
  *CYP2C19*    Forward 5′-GTATTTTGGCCTGGAACGCA-3′
               Reverse 5′-CAGTGGGAAATGGCCTCTTC-3′
  *CYP2D6*     Forward 5′-ACCAGGCTCACATGCCCTA-3′
               Reverse 5′-TTCGATGTCACGGGATGTCAT-3′
  *DDIT3*      Forward 5′-TGTTAAAGATGAGCGGGTGG-3′
               Reverse 5′-TGCTTTCAGGTGTGGTGATG-3′
  *EP300*      Forward 5′-AAATGGCCGAGAATGTGGTG-3′
               Reverse 5′-TGGTAAGTCGTGCTCCAAGT-3′
  *ERBB3*      Forward 5′-CAACTCTCAGGCAGTGTGTC-3′
               Reverse 5′-CATCACCACCTCACACCTCT-3′
  *ERCC1*      Forward 5′-ACCCAGACTACATCCATGGG-3′
               Reverse 5′-TCTTAGCCAGCTCCTTGAGG-3′
  *FANCD2*     Forward 5′-GGGATTATTGGTGCTGTGACC-3′
               Reverse 5′-GCTCAGGTTGGCTCTCTCTT-3′
  *FAS*        Forward 5′-GATGAACCAGACTGCGTGC-3′
               Reverse 5′-TCACACAATCTACATCTTCTGCA-3′
  *FLCN*       Forward 5′-GAGGCAGAGCAGTTTGGATG-3′
               Reverse 5′-CACTTGTCAGCGATGTCAGC-3′
  *FH*         Forward 5′-TGTTAGGAGGTGAACTTGGCA-3′
               Reverse 5′-ATGTGCATTGCTGTGGGAAA-3′
  *GNA11*      Forward 5′-TACGAGCAGAACAAGGCCAA-3′
               Reverse 5′-GTCGTAGCATTCCTGGATGC-3′
  *HNF1A*      Forward 5′-GCTGATTGAAGAGCCCACAG-3′
               Reverse 5′-CTCTCGCTCCTCCTTGCTAG-3′
  *IKBKE*      Forward 5′-GAGAAGTTCGTCTCGGTCTATGG-3′
               Reverse 5′-TGCATGGTACAAGGTCACTCC-3′
  *ITGA10*     Forward 5′-ACTTAGGTGACTACCAACTGGG-3′
               Reverse 5′-CCACAAGCACGAGACCAGA-3′
  *IL2*        Forward 5′-AACTCCTGTCTTGCATTGCAC-3′
               Reverse 5′-GCTCCAGTTGTAGCTGTGTTT-3′
  *IL21R*      Forward 5′-CTTCATGGCCGACGACATTT-3′
               Reverse 5′-GGAGAAAGCTGCCACACTC-3′
  *KEAP1*      Forward 5′-TGGCCACATCTATGCCGTC-3′
               Reverse 5′-ATCCTTCGTGTCAGCATTGG-3′
  *KDR*        Forward 5′-GGCCCAATAATCAGAGTGGCA-3′
               Reverse 5′-CCAGTGTCATTTCCGATCACTTT-3′
  *KIT*        Forward 5′-CGTTCTGCTCCTACTGCTTCG-3′
               Reverse 5′-CCCACGCGGACTATTAAGTCT-3′
  *LRP1B*      Forward 5′-CCAACGGTTCTGTATGTGTCA-3′
               Reverse 5′-GCGACATTCCCGTAGTCAGTAAA-3′
  *KAT6B*      Forward 5′-CACCTCAGTATCCCAGTGCA-3′
               Reverse 5′-ATTGGAATGGGATCAGCACG-3′
  *KDM6A*      Forward 5′-TACAGGCTCAGTTGTGTAACCT-3′
               Reverse 5′-CTGCGGGAATTGGTAGGCTC-3′
  *MALT1*      Forward 5′-AAGGTTGCACAGTCACAGAA-3′
               Reverse 5′-ACTGCCTTTGACTCTGGGTT-3′
  *MDM4*       Forward 5′-TGATTGTCGAAGAACCATTTCGG-3′
               Reverse 5′-TGCAGGGATCAAAAAGTTTGGAG-3′
  *MEN1*       Forward 5′-CAACCCTTCCATTGACCTGC-3′
               Reverse 5′-GCTCCTCTAGATCTGCCAGG-3′
  *MPL*        Forward 5′-CTGAAGTGTTTCTCCCGAACAT-3′
               Reverse 5′-GCGGGTAGGCATACAGCAG-3′
  *MSH2*       Forward 5′-AGAGCTGGAAATAAGGCATCC-3′
               Reverse 5′-AACACCCACAACACCAATGG-3′
  *MYH11*      Forward 5′-GGATGAGAGGGACAGAGCTG-3′
               Reverse 5′-GCTTCCAAGGCCTCTTCAAG-3′
  *NTRK1*      Forward 5′-TCAACAACGGCAACTACACG-3′
               Reverse 5′-CTCGGGGTTGAACTCGAAAG-3′
  *NOTCH1*     Forward 5′-TGGACCAGATTGGGGAGTTC-3′
               Reverse 5′-GCACACTCGTCTGTGTTGAC-3′
  *NUMA1*      Forward 5′-GGGCTAAACCTTAATGAGGACC-3′
               Reverse 5′-AGGAAGCGAATCTCCCTCTTG-3′
  *PAX3*       Forward 5′-AGCCGCATCCTGAGAAGTAA-3′
               Reverse 5′-CTTCATCTGATTGGGGTGCT-3′
  *PAX7*       Forward 5′-CAATGGAATGGCAGGGACAC-3′
               Reverse 5′-GATCACACAGCGGTACTTGC-3′
  *PALB2*      Forward 5′-GGAAAGCTCTGGATGCTTGG-3′
               Reverse 5′-CCCAAAGCTACACACACGAG-3′
  *PIK3CD*     Forward 5′-CTGGGGAATTTCAAGACCAAGT-3′
               Reverse 5′-CCCTGCTGAATCACATGGAC-3′
  *PIK3CG*     Forward 5′-AGTATGACGTCAGTTCCCAAGT-3′
               Reverse 5′-GGAACTCTAAAGCTTTCGGGG-3′
  *PIK3C2B*    Forward 5′-CTGGCTATGTCTGGAGTGCT-3′
               Reverse 5′-CAGTGGAGGAACAGTTGCAG-3′
  *PLAG1*      Forward 5′-AAACTTTTGAAAGCACGGGAGT-3′
               Reverse 5′-GGCGATCACAATGTTCGCAC-3′
  *PDGFRB*     Forward 5′-TGATGCCGAGGAACTATTCATCT-3′
               Reverse 5′-TTTCTTCTCGTGCAGTGTCAC-3′
  *PDGFB*      Forward 5′-ACTCGATCCGCTCCTTTGAT-3′
               Reverse 5′-GGGTCATGTTCAGGTCCAAC-3′
  *PKHD1*      Forward 5′-GCTCCGCTTCTTTCCTTCAC-3′
               Reverse 5′-AGAGTGGTGCCAGTGACATT-3′
  *PRDM1*      Forward 5′-TAAAGCAACCGAGCACTGAGA-3′
               Reverse 5′-ACGGTAGAGGTCCTTTCCTTTG-3′
  *PTGS2*      Forward 5′-TCCCTTCCTTCGAAATGCAA-3′
               Reverse 5′-GAGGTTAGAGAAGGCTTCCCA-3′
  *PTPRT*      Forward 5′-CAATGGAATGGCAGGGACAC-3′
               Reverse 5′-GATCACACAGCGGTACTTGC-3′
  *RECQL4*     Forward 5′-CCCTGCTGTCACTCATGGAT-3′
               Reverse 5′-GACAGATTCCCGTTGCTTCC-3′
  *REL*        Forward 5′-TCCTCCTGTTGTCTCGAACC-3′
               Reverse 5′-CCTCCTCTGACACTTCCACA-3′
  *RUNX1*      Forward 5′-CATCGCTTTCAAGGTGGTGG-3′
               Reverse 5′-GTTCTTCATGGCTGCGGTAG-3′
  *SMO*        Forward 5′-TCGAATCGCTACCCTGCTG-3′
               Reverse 5′-CAAGCCTCATGGTGCCATCT-3′
  *SAMD9*      Forward 5′-ATGGCAAAGCAACTTAACCTTCC-3′
               Reverse 5′-CCATTCACGTCTTGTTCAGTCA-3′
  *TAF1L*      Forward 5′-TCCCTCAGTACGTCTCGAGA-3′
               Reverse 5′-TCTGGAGTGGCAGTGGAAAT-3′
  *TET1*       Forward 5′-CATCAGTCAAGACTTTAAGCCCT-3′
               Reverse 5′-CGGGTGGTTTAGGTTCTGTTT-3′
  *TNFAIP3*    Forward 5′-ACCCCATTGTTCTCGGCTAT-3′
               Reverse 5′-AATCTTCCCCGGTCTCTGTT-3′
  *TCF12*      Forward 5′-CTCCTGACCATACCAGCAGT-3′
               Reverse 5′-CTTGGGGATGAAGGTGCTTG-3′
  *β-actin*    Forward 5′-GAATGATGAGCCTTCGTGCC-3′
               Reverse 5′-GGTCTCAAGTCAGTGTACAGG-3′

###### 

Number of SNVs exhibiting a potential association with sensitivity to 9 anticancer drugs in a screening study of 59 xenografts.

  Anticancer drug   SNVs
  ----------------- ------
  5FU               61
  ACNU              64
  ADR               76
  CPM               65
  DDP               59
  MMC               98
  MTX               43
  VCR               85
  VLB               45

SNV, single nucleotide variant; 5FU, 5-fluorouracil; ACNU, nimustine; ADR, adriamycin; CPM, cyclophosphamide; DDP, cisplatin; MMC, mitomycin C; MTX, methotrexate; VCR, vincristine; VLB, vinblastine.

###### 

Single nucleotide variants potentially associated with sensitivity to 5-fluorouracil.

                                                                                 Variant allele frequency             
  ----- ---- ------------ ----------- ---------- ----- ----------- ------------- -------------------------- ---- ---- ---------
    1   1    rs11121691   11181327    *MTOR*     C/T   Sensitive   Screening     52                         3    1    0.00536
                                                                   Replication   19                         1    0    NA
                                                                   Combined      71                         4    1    0.03340
    2   14   rs8020503    51239067    *NIN*      C/G   Sensitive   Screening     25                         0    31   0.00668
                                                                   Replication   5                          1    14   0.67994
                                                                   Combined      30                         1    45   0.01397
    3   2    rs1128919    148657117   *ACVR2A*   G/A   Sensitive   Screening     15                         28   13   0.01129
                                                                   Replication   3                          6    11   0.23334
                                                                   Combined      18                         34   24   0.11270
    4   7    rs3802064    92731586    *SAMD9*    A/G   Resistant   Screening     46                         8    2    0.01191
                                                                   Replication   17                         2    1    0.83228
                                                                   Combined      63                         10   3    0.02524
    5   18   --           22642739    *ZNF521*   A/G   Sensitive   Screening     43                         13   0    0.01218
                                                                   Replication   19                         1    0    NA
                                                                   Combined      62                         14   0    0.00564
    6   7    rs78644495   98552958    *TRRAP*    G/A   Resistant   Screening     46                         10   0    0.01244
                                                                   Replication   15                         5    0    0.51253
                                                                   Combined      61                         15   0    0.10691
    7   10   rs2435352    43600689    *RET*      A/G   Resistant   Screening     34                         16   6    0.01268
                                                                   Replication   11                         4    5    0.78343
                                                                   Combined      45                         20   11   0.02998
    8   10   rs11574851   104160959   *NFKB2*    C/T   Sensitive   Screening     46                         9    1    0.01305
                                                                   Replication   15                         1    4    0.17591
                                                                   Combined      61                         10   5    0.01631
    9   22   rs3818120    41523770    *EP300*    G/A   Resistant   Screening     47                         9    0    0.01354
                                                                   Replication   16                         3    1    0.04714
                                                                   Combined      63                         12   1    0.41164
  10    22   rs20554      41553259    *EP300*    G/A   Resistant   Screening     47                         9    0    0.01354
                                                                   Replication   16                         3    1    0.04714
                                                                   Combined      63                         12   1    0.41164

The top 10 variants that revealed the smallest P-values in the screening study. Chr, chromosome; SNP, single nucleotide polymorphism; SNP ID, rs ID from the NCBI database of genetic variation (dbSNP). '−', this variant is not identified in dbSNP; Ref., reference; NA, not available.

###### 

Single nucleotide variants potentially associated with sensitivity to nimustine.

                                                                                   Variant allele frequency             
  ----- ---- ------------ ------------- ---------- ----- ----------- ------------- -------------------------- ---- ---- ---------
    1   19   rs3218066    30,312,874    *CCNE1*    C/T   Sensitive   Screening     38                         18   1    0.00224
                                                                     Replication   16                         3    1    0.92463
                                                                     Combined      54                         21   2    0.00379
    2   19   rs3218068    30,313,344    *CCNE1*    T/C   Sensitive   Screening     38                         18   1    0.00224
                                                                     Replication   16                         3    1    0.92463
                                                                     Combined      54                         21   2    0.00379
    3   4    rs7688174    40,244,982    *RHOH*     C/G   Resistant   Screening     53                         1    3    0.00828
                                                                     Replication   19                         1    0    NA
                                                                     Combined      72                         2    3    0.02986
    4   5    rs6962       256,509       *SDHA*     G/A   Resistant   Screening     51                         6    0    0.01003
                                                                     Replication   19                         1    0    NA
                                                                     Combined      70                         7    0    0.00849
    5   11   rs5030171    32,449,417    *WT1*      C/G   Resistant   Screening     12                         17   28   0.01085
                                                                     Replication   2                          6    12   0.92759
                                                                     Combined      14                         23   40   0.01873
    6   11   rs5030170    32,449,420    *WT1*      C/A   Resistant   Screening     12                         17   28   0.01085
                                                                     Replication   2                          6    12   0.92759
                                                                     Combined      14                         23   40   0.01873
    7   5    rs10039029   251,469       *SDHA*     G/A   Resistant   Screening     49                         7    1    0.01148
                                                                     Replication   19                         1    0    NA
                                                                     Combined      68                         8    1    0.01366
    8   1    rs76717731   193,107,192   *CDC73*    C/T   Resistant   Screening     52                         5    0    0.01303
                                                                     Replication   16                         3    1    0.53863
                                                                     Combined      68                         8    1    0.08246
    9   11   rs74662318   4,150,239     *RRM1*     T/G   Resistant   Screening     48                         9    0    0.01422
                                                                     Replication   17                         3    0    0.56000
                                                                     Combined      65                         12   0    0.02893
  10    5    rs28363396   138,148,036   *CTNNA1*   A/G   Sensitive   Screening     51                         6    0    0.01557
                                                                     Replication   18                         2    0    0.16531
                                                                     Combined      69                         8    0    0.20441

The top 10 variants that revealed the smallest P-values in the screening study. Chr, chromosome; SNP, single nucleotide polymorphism; SNP ID, rs ID from the NCBI database of genetic variation (dbSNP). '−', this variant is not identified in dbSNP; Ref., reference; NA, not available.

###### 

Single nucleotide variants potentially associated with sensitivity to adriamycin.

                                                                                   Variant allele frequency             
  ----- ---- ------------- ------------- --------- ----- ----------- ------------- -------------------------- ---- ---- ---------
    1   11   rs77233576    44,130,665    *EXT2*    A/C   Resistant   Screening     51                         5    1    0.00115
                                                                     Replication   14                         5    1    0.43313
                                                                     Combined      65                         10   2    0.01565
    2   9    rs464826      136,913,355   *BRD3*    T/C   Resistant   Screening     15                         15   27   0.00131
                                                                     Replication   5                          7    8    0.88274
                                                                     Combined      20                         22   35   0.03060
    3   2    rs117225004   141,259,253   *LRP1B*   T/C   Resistant   Screening     53                         3    1    0.00315
                                                                     Replication   20                         0    0    NA
                                                                     Combined      73                         3    1    0.00355
    4   15   rs2229765     99,478,225    *IGF1R*   G/A   Resistant   Screening     26                         25   6    0.00363
                                                                     Replication   10                         7    3    0.58702
                                                                     Combined      36                         32   9    0.01565
    5   15   rs2293117     99,478,713    *IGF1R*   T/C   Resistant   Screening     26                         25   6    0.00363
                                                                     Replication   10                         7    3    0.58702
                                                                     Combined      36                         32   9    0.01565
    6   7    rs113962761   50,450,446    *IKZF1*   C/T   Resistant   Screening     47                         10   0    0.00365
                                                                     Replication   19                         1    0    NA
                                                                     Combined      66                         11   0    0.00147
    7   5    rs16903989    38,504,303    *LIFR*    A/T   Sensitive   Screening     28                         23   6    0.00509
                                                                     Replication   14                         5    1    0.59174
                                                                     Combined      42                         28   7    0.03189
    8   1    rs138622243   47,691,061    *TAL1*    G/T   Sensitive   Screening     54                         2    1    0.00591
                                                                     Replication   19                         0    1    NA
                                                                     Combined      73                         2    2    0.00764
    9   22   rs180812      23,657,735    *BCR*     G/A   Resistant   Screening     30                         3    24   0.00662
                                                                     Replication   8                          1    11   0.33467
                                                                     Combined      38                         4    35   0.01663
  10    6    rs12196767    51,776,535    *PKHD1*   T/C   Resistant   Screening     41                         15   1    0.00950
                                                                     Replication   14                         6    0    0.59174
                                                                     Combined      55                         21   1    0.01484

The top 10 variants that revealed the smallest P-values in the screening study. Chr, chromosome; SNP, single nucleotide polymorphisms; SNP ID, rs ID from the NCBI database of genetic variation (dbSNP). '−', this variant is not identified in dbSNP; Ref., reference; NA, not available.

###### 

Single nucleotide variants potentially associated with sensitivity to cyclophosphamide.

                                                                                   Variant allele frequency             
  ----- ---- ------------ ------------- ---------- ----- ----------- ------------- -------------------------- ---- ---- ---------
    1   6    rs4331993    152,793,572   *SYNE1*    T/A   Resistant   Screening     48                         4    7    0.00119
                                                                     Replication   16                         4    0    0.60273
                                                                     Combined      64                         8    7    0.00139
    2   6    rs1024195    56,507,135    *DST*      T/C   Sensitive   Screening     24                         23   12   0.00188
                                                                     Replication   10                         6    4    0.27755
                                                                     Combined      34                         29   16   0.14291
    3   2    rs79555258   148,680,526   *ACVR2A*   T/C   Resistant   Screening     55                         3    1    0.00312
                                                                     Replication   18                         0    2    0.02313
                                                                     Combined      73                         3    3    0.00109
    4   12   rs3217786    4,383,158     *CCND2*    T/C   Resistant   Screening     24                         3    32   0.00378
                                                                     Replication   5                          0    15   0.12606
                                                                     Combined      29                         3    47   0.00247
    5   14   rs8020503    51,239,067    *NIN*      C/G   Resistant   Screening     27                         0    32   0.00602
                                                                     Replication   5                          1    14   0.09672
                                                                     Combined      32                         1    46   0.07844
    6   5    rs28363396   138,148,036   *CTNNA1*   A/G   Sensitive   Screening     53                         6    0    0.00675
                                                                     Replication   18                         2    0    0.84988
                                                                     Combined      71                         8    0    0.02011
    7   18   --           22,642,750    *ZNF521*   G/C   Resistant   Screening     55                         4    0    0.00796
                                                                     Replication   19                         1    0    NA
                                                                     Combined      74                         5    0    0.10716
    8   7    rs2360885    151,971,043   *MLL3*     T/C   Resistant   Screening     22                         37   0    0.00844
                                                                     Replication   0                          20   0    NA
                                                                     Combined      22                         57   0    0.03116
    9   3    --           128,202,753   *GATA2*    G/A   Resistant   Screening     10                         49   0    0.00862
                                                                     Replication   0                          20   0    NA
                                                                     Combined      10                         69   0    0.01830
  10    14   rs1152783    99,642,360    *BCL11B*   C/G   Resistant   Screening     52                         6    1    0.00895
                                                                     Replication   16                         3    1    0.92461
                                                                     Combined      68                         9    2    0.12611

The top 10 variants that revealed the smallest P-values in the screening study. Chr, chromosome; SNP, single nucleotide polymorphisms; SNP ID, rs ID from the NCBI database of genetic variation (dbSNP). '−', this variant is not identified in dbSNP; Ref., reference; NA, not available.

###### 

Single nucleotide variants potentially associated with sensitivity to cisplatin.

                                                                                   Variant allele frequency             
  ----- ---- ------------ ------------- ---------- ----- ----------- ------------- -------------------------- ---- ---- ---------
    1   18   --           22,642,741    *ZNF521*   A/G   Resistant   Screening     34                         23   0    0.00331
                                                                     Replication   11                         9    0    0.51842
                                                                     Combined      45                         32   0    0.02421
    2   6    rs2228480    152,420,095   *ESR1*     G/A   Resistant   Screening     44                         8    5    0.00403
                                                                     Replication   15                         3    2    0.58609
                                                                     Combined      59                         11   7    0.00419
    3   17   rs11653832   5,424,906     *NLRP1*    C/G   Sensitive   Screening     54                         1    2    0.00774
                                                                     Replication   19                         0    1    NA
                                                                     Combined      73                         1    3    0.11849
    4   17   rs11653580   5,424,991     *NLRP1*    G/A   Sensitive   Screening     54                         1    2    0.00774
                                                                     Replication   19                         0    1    NA
                                                                     Combined      73                         1    3    0.11849
    5   17   rs56872041   5,433,841     *NLRP1*    A/G   Sensitive   Screening     54                         1    2    0.00774
                                                                     Replication   19                         0    1    NA
                                                                     Combined      73                         1    3    0.11849
    6   17   rs35596958   5,433,966     *NLRP1*    T/C   Sensitive   Screening     54                         1    2    0.00774
                                                                     Replication   19                         0    1    NA
                                                                     Combined      73                         1    3    0.11849
    7   17   rs34733791   5,437,285     *NLRP1*    G/A   Sensitive   Screening     54                         1    2    0.00774
                                                                     Replication   19                         0    1    NA
                                                                     Combined      73                         1    3    0.11849
    8   18   rs79073678   56,414,592    *MALT1*    T/C   Sensitive   Screening     43                         6    8    0.00953
                                                                     Replication   15                         3    2    0.81174
                                                                     Combined      58                         9    10   0.02702
    9   1    rs1318056    179,112,145   *ABL2*     C/G   Sensitive   Screening     54                         1    2    0.01006
                                                                     Replication   18                         2    0    0.61429
                                                                     Combined      72                         3    2    0.05767
  10    10   rs755793     123,310,871   *FGFR2*    A/G   Sensitive   Screening     52                         3    2    0.01078
                                                                     Replication   18                         2    0    0.89974
                                                                     Combined      70                         5    2    0.03628

The top 10 variants that revealed the smallest P-values in the screening study. Chr, chromosome; SNP, single nucleotide polymorphism; SNP ID, rs ID from the NCBI database of genetic variation (dbSNP). '−', this variant is not identified in dbSNP; Ref., reference; NA, not available.

###### 

Single nucleotide variants potentially associated with sensitivity to mitomycin C.

                                                                                  Variant allele frequency             
  ---- ---- ------------ ------------- ---------- ----- ----------- ------------- -------------------------- ---- ---- ---------
  1    2    rs13382825   141,528,435   *LRP1B*    T/C   Resistant   Screening     49                         9    1    0.00092
                                                                    Replication   17                         1    2    0.25630
                                                                    Combined      66                         10   3    0.00793
  2    7    rs2230585    100,410,597   *EPHB4*    G/A   Resistant   Screening     34                         14   11   0.00266
                                                                    Replication   8                          8    4    0.01083
                                                                    Combined      42                         22   15   0.01284
  3    5    rs216123     149,460,553   *CSF1R*    A/G   Sensitive   Screening     42                         13   4    0.00310
                                                                    Replication   13                         3    4    0.24816
                                                                    Combined      55                         16   8    0.00728
  4    11   rs2295081    32,439,038    *WT1*      T/C   Resistant   Screening     15                         20   24   0.00431
                                                                    Replication   3                          4    13   0.98644
                                                                    Combined      18                         24   37   0.04518
  5    9    rs686346     135,978,378   *RALGDS*   T/C   Resistant   Screening     33                         16   10   0.00591
                                                                    Replication   7                          8    5    0.05342
                                                                    Combined      40                         24   15   0.00397
  6    11   rs16754      32,417,945    *WT1*      T/C   Resistant   Screening     16                         20   23   0.00723
                                                                    Replication   20                         0    0    NA
                                                                    Combined      36                         20   23   0.01174
  7    14   rs17111401   81,528,412    *TSHR*     T/A   Sensitive   Screening     42                         9    8    0.00758
                                                                    Replication   17                         1    2    0.63346
                                                                    Combined      59                         10   10   0.04605
  8    18   --           22,642,750    *ZNF521*   G/C   Resistant   Screening     55                         4    0    0.00794
                                                                    Replication   19                         1    0    NA
                                                                    Combined      74                         5    0    0.09450
  9    7    rs56173078   100,420,155   *EPHB4*    A/G   Sensitive   Screening     55                         3    1    0.00907
                                                                    Replication   20                         0    0    NA
                                                                    Combined      75                         3    1    0.01301
  10   5    rs2229992    112,162,854   *APC*      T/C   Resistant   Screening     6                          19   34   0.00954
                                                                    Replication   2                          6    12   0.48368
                                                                    Combined      8                          25   46   0.06409

The top 10 variants that revealed the smallest P-values in the screening study. Chr, chromosome; SNPs, single nucleotide polymorphism; SNP ID, rs ID from the NCBI database of genetic variation (dbSNP). '−', this variant is not identified in dbSNP; Ref., reference; NA, not available.

###### 

Single nucleotide variants possibly associated with sensitivity to methotrexate.

                                                                                     Variant allele frequency             
  ----- ---- ------------ ------------- ------------ ----- ----------- ------------- -------------------------- ---- ---- ---------
    1   2    rs62154469   100,209,627   *AFF3*       C/T   Sensitive   Screening     38                         10   2    0.00146
                                                                       Replication   14                         3    1    0.07029
                                                                       Combined      52                         13   3    0.15022
    2   18   --           22,642,744    *ZNF521*     A/G   Resistant   Screening     28                         22   0    0.00317
                                                                       Replication   11                         7    0    0.68283
                                                                       Combined      39                         29   0    0.01315
    3   9    rs4489420    139,418,260   *NOTCH1*     A/G   Sensitive   Screening     2                          9    39   0.00457
                                                                       Replication   2                          0    16   0.20492
                                                                       Combined      4                          9    55   0.02555
    4   19   rs1048290    10,600,442    *KEAP1*      G/C   Sensitive   Screening     22                         11   17   0.00778
                                                                       Replication   5                          4    9    0.01099
                                                                       Combined      27                         15   26   0.03367
    5   1    rs4870       2,488,153     *TNFRSF14*   A/G   Sensitive   Screening     35                         11   4    0.00822
                                                                       Replication   9                          5    4    0.06420
                                                                       Combined      44                         16   8    0.04414
    6   6    rs7747060    56,476,262    *DST*        T/C   Resistant   Screening     28                         17   5    0.01127
                                                                       Replication   12                         3    3    0.80779
                                                                       Combined      40                         20   8    0.04457
    7   6    rs17215781   152,570,274   *SYNE1*      A/G   Sensitive   Screening     47                         3    0    0.01305
                                                                       Replication   18                         0    0    NA
                                                                       Combined      65                         3    0    0.02790
    8   19   rs273269     18,279,638    *PIK3R2*     T/C   Sensitive   Screening     1                          2    47   0.01342
                                                                       Replication   0                          0    18   NA
                                                                       Combined      1                          2    65   0.01020
    9   5    rs75732095   149,495,537   *PDGFRB*     G/A   Sensitive   Screening     28                         15   7    0.01376
                                                                       Replication   12                         3    3    0.94673
                                                                       Combined      40                         18   10   0.07319
  10    15   rs316618     41,796,498    *LTK*        T/A   Resistant   Screening     47                         3    0    0.01383
                                                                       Replication   17                         0    1    NA
                                                                       Combined      64                         3    1    0.00644

The top 10 variants that revealed the smallest P-values in the screening study. Chr, chromosome; SNP, single nucleotide polymorphism; SNP ID, rs ID from the NCBI database of genetic variation (dbSNP). '−', this variant is not identified in dbSNP; Ref., reference; NA, not available.

###### 

Single nucleotide variants potentially associated with sensitivity to vincristine.

                                                                                    Variant allele frequency             
  ----- ---- ------------- ------------- ---------- ----- ----------- ------------- -------------------------- ---- ---- ---------
    1   7    rs1805321     6,026,988     *PMS2*     G/A   Sensitive   Screening     24                         15   17   0.00018
                                                                      Replication   10                         6    4    0.93002
                                                                      Combined      34                         21   21   0.00172
    2   7    rs62456182    6,038,722     *PMS2*     T/C   Sensitive   Screening     22                         18   16   0.00054
                                                                      Replication   10                         6    4    0.93002
                                                                      Combined      32                         24   20   0.00372
    3   1    rs2453056     120,477,998   *NOTCH2*   C/A   Resistant   Screening     52                         3    1    0.00293
                                                                      Replication   20                         0    0    NA
                                                                      Combined      72                         3    1    0.00437
    4   17   rs1136201     37,879,588    *ERBB2*    A/G   Resistant   Screening     47                         8    1    0.00386
                                                                      Replication   14                         4    2    0.21126
                                                                      Combined      61                         12   3    0.01309
    5   7    rs2228006     6,026,775     *PMS2*     T/C   Sensitive   Screening     1                          4    51   0.00508
                                                                      Replication   1                          3    16   0.29807
                                                                      Combined      2                          7    67   0.57955
    6   3    rs3732565     134,968,232   *EPHB1*    C/T   Sensitive   Screening     49                         7    0    0.00927
                                                                      Replication   18                         1    1    0.84994
                                                                      Combined      67                         8    1    0.06335
    7   1    rs5277        186,648,197   *PTGS2*    C/G   Sensitive   Screening     50                         5    1    0.01139
                                                                      Replication   18                         2    0    0.70514
                                                                      Combined      68                         7    1    0.01819
    8   9    rs2290889     93,639,849    *SYK*      G/A   Sensitive   Screening     50                         5    1    0.01183
                                                                      Replication   19                         1    0    NA
                                                                      Combined      69                         6    1    0.02838
    9   3    rs762803844   71,247,577    *FOXP1*    G/T   Sensitive   Screening     45                         11   0    0.01185
                                                                      Replication   20                         0    0    NA
                                                                      Combined      65                         11   0    0.04620
  10    5    rs16903989    38,504,303    *LIFR*     A/T   Sensitive   Screening     27                         23   6    0.01225
                                                                      Replication   14                         5    1    0.09051
                                                                      Combined      41                         28   7    0.00983

The top 10 variants that revealed the smallest P-values in the screening study. Chr, chromosome; SNPs, single nucleotide polymorphisms; SNP ID, rs ID from the NCBI database of genetic variation (dbSNP). '−', this variant is not identified in dbSNP; Ref., reference; NA, not available.

###### 

Single nucleotide variants potentially associated with sensitivity to vinblastine.

                                                                                    Variant allele frequency             
  ---- ---- ------------- ------------- ----------- ----- ----------- ------------- -------------------------- ---- ---- ---------
  1    5    rs351855      176,520,243   *FGFR4*     G/A   Resistant   Screening     22                         22   12   0.00337
                                                                      Replication   8                          6    6    0.08904
                                                                      Combined      30                         28   18   0.00225
  2    18   --            22,642,741    *ZNF521*    A/G   Resistant   Screening     33                         23   0    0.00613
                                                                      Replication   11                         9    0    0.42416
                                                                      Combined      44                         32   0    0.08059
  3    18   rs79073678    56,414,592    *MALT1*     T/C   Sensitive   Screening     42                         6    8    0.00676
                                                                      Replication   15                         3    2    0.89077
                                                                      Combined      57                         9    10   0.05146
  4    3    --            37,067,095    *MLH1*      A/T   Sensitive   Screening     49                         7    0    0.00960
                                                                      Replication   9                          11   0    0.34137
                                                                      Combined      58                         18   0    0.15800
  5    1    rs117505788   6,535,149     *PLEKHG5*   A/G   Resistant   Screening     52                         3    1    0.01140
                                                                      Replication   18                         2    0    0.84983
                                                                      Combined      70                         5    1    0.20339
  6    9    rs16909898    98,231,008    *PTCH1*     A/G   Resistant   Screening     46                         8    2    0.01377
                                                                      Replication   18                         1    1    0.34380
                                                                      Combined      64                         9    3    0.01214
  7    9    rs1805155     98,238,379    *PTCH1*     A/G   Resistant   Screening     46                         8    2    0.01377
                                                                      Replication   18                         1    1    0.34380
                                                                      Combined      64                         9    3    0.01214
  8    9    rs28448271    98,239,730    *PTCH1*     G/A   Resistant   Screening     46                         8    2    0.01377
                                                                      Replication   18                         1    1    0.34380
                                                                      Combined      64                         9    3    0.01214
  9    11   rs77233576    44,130,665    *EXT2*      A/C   Resistant   Screening     50                         5    1    0.01647
                                                                      Replication   14                         5    1    0.62003
                                                                      Combined      64                         10   2    0.59593
  10   3    rs59684491    37,067,097    *MLH1*      A/T   Sensitive   Screening     49                         6    1    0.01677
                                                                      Replication   13                         6    1    0.96834
                                                                      Combined      62                         12   2    0.08250

The top 10 variants that revealed the smallest P-values in the screening study. Chr, chromosome; SNPs, single nucleotide polymorphisms; SNP ID, rs ID from the NCBI database of genetic variation (dbSNP). '−', this variant is not identified in dbSNP; Ref., reference; NA, not available.

###### 

Summary of results for screening and replication study of 35 single nucleotide variants associated with sensitivity to cytotoxic anticancer drugs.

                                                                                                                                                                           Prediction of functional effect                           Number of samples in VAF group        Expression                          
  ---------------------------------------------------- ------ ---- ------------- ------------- --------------------------------------------------------- ----- ----------- --------------------------------- ----------- ----------- -------------------------------- ---- ------------ ---- --------- ------- --------
    1                                                  CPM    2    rs79555258    148,680,526   *ACVR2A*                                                  T/C   Intron 9                                                  Resistant   Screening                        55   3            1    0.00312   −0.02   0.85
                                                                                                                                                                                                                                     Replication                      18   0            2    0.02313           
                                                                                                                                                                                                                                     Combined                         73   3            3    0.00109           
    2                                                  ACNU   1    rs3218625     186,643,541   *PTGS2*                                                   C/T   Exon 10     Benign                            Tolerated   Sensitive   Screening                        55   2            0    0.04147   −0.30   0.15
                                                                                                                                                               (G587R)     (0.012)                           (0.43)                  Replication                      17   3            0    0.00807           
                                                                                                                                                                                                                                     Combined                         72   5            0    0.00117           
    3^[a](#tfn12-etm-0-0-5533){ref-type="table-fn"}^   ACNU   8    rs201432181   37,699,794    *GPR124*^[a](#tfn12-etm-0-0-5533){ref-type="table-fn"}^   A/T   Exon 19     Possibly                          Tolerated   Sensitive   Screening                        55   2            0    0.02030   0.14    0.47
                                                                                                                                                               (D1313V)    damaging                          (0.12)                  Replication                      18   2            0    0.02319           
                                                                                                                                                                           (0.664)                                                   Combined                         73   4            0    0.00126           
                                                       MMC    8    rs201432181   37,699,794    *GPR124*^[a](#tfn12-etm-0-0-5533){ref-type="table-fn"}^   A/T   Exon 19     Possibly                          Tolerated   Sensitive   Screening                        57   2            0    0.02117   −0.28   0.15
                                                                                                                                                               (D1313V)    damaging                          (0.12)                  Replication                      18   2            0    0.18538           
                                                                                                                                                                           (0.664)                                                   Combined                         75   4            0    0.00404           
                                                       VLB    8    rs201432181   37,699,794    *GPR124*^[a](#tfn12-etm-0-0-5533){ref-type="table-fn"}^   A/T   Exon 19     Possibly                          Tolerated   Sensitive   Screening                        54   2            0    0.03044   −0.16   0.42
                                                                                                                                                               (D1313V)    damaging                          (0.12)                  Replication                      18   2            0    0.84983           
                                                                                                                                                                           (0.664)                                                   Combined                         72   4            0    0.01706           
                                                       ADR    8    rs201432181   37,699,794    *GPR124*^[a](#tfn12-etm-0-0-5533){ref-type="table-fn"}^   A/T   Exon 19     Possibly                          Tolerated   Sensitive   Screening                        55   2            0    0.03933   0.31    0.11
                                                                                                                                                               (D1313V)    damaging                          (0.12)                  Replication                      18   2            0    0.61416           
                                                                                                                                                                           (0.664)                                                   Combined                         73   4            0    0.02917           
    4                                                  ADR    7    rs113962761   50,450,446    *IKZF1*                                                   C/T   Intron 5                                                  Resistant   Screening                        47   10           0    0.00365   −0.07   0.54
                                                                                                                                                                                                                                     Replication                      19   1            0    NA                
                                                                                                                                                                                                                                     Combined                         66   11           0    0.00147           
    5                                                  CPM    2    rs2020910     48,030,692    *MSH6*                                                    T/A   Exon 5                                                    Sensitive   Screening                        39   18           2    0.04828   0.20    0.09
                                                                                                                                                               (T1102T)                                                              Replication                      12   6            2    0.03822           
                                                                                                                                                                                                                                     Combined                         51   24           4    0.00243           
    6                                                  CPM    12   rs3217786     4,383,158     *CCND2*                                                   T/C   Exon 1                                                    Resistant   Screening                        24   3            32   0.00378   0.02    0.84
                                                                                                                                                               (3′UTR)                                                               Replication                      5    0            15   0.12606           
                                                                                                                                                                                                                                     Combined                         29   3            47   0.00247           
    7                                                  ADR    7    rs1050171     55,249,063    *EGFR*                                                    G/A   Exon 20                                                   Resistant   Screening                        37   16           4    0.04670   0.22    0.06
                                                                                                                                                               (Q787Q)                                                               Replication                      16   4            0    0.01812           
                                                                                                                                                                                                                                     Combined                         53   20           4    0.00288           
    8                                                  5FU    18   --            22,642,739    *ZNF521*                                                  A/G   Intron 7                                                  Sensitive   Screening                        43   13           0    0.01218   −0.39   0.002
                                                                                                                                                                                                                                     Replication                      19   1            0    NA                
                                                                                                                                                                                                                                     Combined                         62   14           0    0.00564           
    9                                                  ADR    2    rs4589708     29,498,210    *ALK*                                                     A/G   Intron 10                                                 Sensitive   Screening                        4    8            45   0.04147   0.37    0.47
                                                                                                                                                                                                                                     Replication                      1    2            17   0.11220           
                                                                                                                                                                                                                                     Combined                         5    10           62   0.00652           
  10                                                   MTX    14   rs3730344     105,241,576   *AKT1*                                                    G/A   Intron 5                                                  Sensitive   Screening                        47   3            0    0.01466   −0.03   0.86
                                                                                                                                                                                                                                     Replication                      17   1            0    NA                
                                                                                                                                                                                                                                     Combined                         64   4            0    0.00666           
  11                                                   5FU    2    rs1863703     219,544,388   *STK36*                                                   A/G   Exon 8      Benign                            Tolerated   Sensitive   Screening                        48   8            0    0.02328   0.01    0.91
                                                                                                                                                               (K295R)     (0.056)                           (0.35)                  Replication                      17   1            2    0.06387           
                                                                                                                                                                                                                                     Combined                         65   9            2    0.00724           
  12                                                   5FU    2    rs16859180    219,553,468   *STK36*                                                   C/T   Exon 12     Probably                          Damaging    Sensitive   Screening                        48   8            0    0.02328   0.01    0.91
                                                                                                                                                               (R477W)     damaging                          (0.00)                  Replication                      17   1            2    0.06387           
                                                                                                                                                                           (1.000)                                                   Combined                         65   9            2    0.00724           
  13                                                   5FU    2    rs12993599    219,563,602   *STK36*                                                   G/A   Exon 26     Benign                            Tolerated   Sensitive   Screening                        48   8            0    0.02328   0.01    0.91
                                                                                                                                                               (R1112Q)    (0.071)                           (1.00)                  Replication                      17   1            2    0.06387           
                                                                                                                                                                                                                                     Combined                         65   9            2    0.00724           
  14                                                   ACNU   5    rs6962        256,509       *SDHA*                                                    G/A   Exon 15     Benign                            Tolerated   Resistant   Screening                        51   6            0    0.01003   0.08    0.47
                                                                                                                                                               (V657I)     (0.021)                           (0.62)                  Replication                      19   1            0    NA                
                                                                                                                                                                                                                                     Combined                         70   7            0    0.00849           
  15                                                   5FU    1    rs1699760     144,852,545   *PDE4DIP*                                                 C/T   Intron 43                                                 Resistant   Screening                        45   11           0    0.01420   −0.16   0.17
                                                                                                                                                                                                                                     Replication                      10   10           0    0.24114           
                                                                                                                                                                                                                                     Combined                         55   21           0    0.00879           
  16^[b](#tfn13-etm-0-0-5533){ref-type="table-fn"}^    VCR    5    rs16903989    38,504,303    *LIFR*^[b](#tfn13-etm-0-0-5533){ref-type="table-fn"}^     A/T   Intron 9                                                  Sensitive   Screening                        27   23           6    0.01225   0.42    0.0003
                                                                                                                                                                                                                                     Replication                      14   5            1    0.09051           
                                                                                                                                                                                                                                     Combined                         41   28           7    0.00983           
                                                       CPM    5    rs16903989    38,504,303    *LIFR*^[b](#tfn13-etm-0-0-5533){ref-type="table-fn"}^     A/T   Intron 9                                                  Sensitive   Screening                        29   24           6    0.04242   0.36    0.002
                                                                                                                                                                                                                                     Replication                      14   5            1    0.09852           
                                                                                                                                                                                                                                     Combined                         43   29           7    0.02571           
  17                                                   5FU    1    rs71664012    144,881,666   *PDE4DIP*                                                 C/A   Intron 24                                                 Resistant   Screening                        16   40           0    0.02674   −0.16   0.17
                                                                                                                                                                                                                                     Replication                      5    15           0    0.23847           
                                                                                                                                                                                                                                     Combined                         21   55           0    0.01311           
  18                                                   MMC    8    rs17847568    30,973,938    *WRN*                                                     C/T   Exon 20     Possibly                          Damaging    Resistant   Screening                        57   0            2    0.04210   0.05    0.82
                                                                                                                                                               (T781I)     damaging                          (0.02)                  Replication                      19   1            0    NA                
                                                                                                                                                                           (0.807)                                                   Combined                         76   1            2    0.01375           
  19                                                   MMC    7    rs78004519    151,860,023   *MLL3*                                                    A/G   Exon 43     Benign                            Tolerated   Resistant   Screening                        57   2            0    0.04887   0.13    0.34
                                                                                                                                                               (S3547P)    (0.033)                           (0.30)                  Replication                      19   1            0    NA                
                                                                                                                                                                                                                                     Combined                         76   3            0    0.01530           
  20                                                   ACNU   8    rs75858201    103,308,010   *UBR5*                                                    T/C   Exon 29                                                   Resistant   Screening                        54   3            0    0.04531   −0.11   0.37
                                                                                                                                                               (K1222K)                                                              Replication                      19   1            0    NA                
                                                                                                                                                                                                                                     Combined                         73   4            0    0.01592           
  21                                                   MMC    8    rs138106214   90,947,858    *NBN*                                                     G/A   Intron 15                                                 Resistant   Screening                        56   3            0    0.04167   0.13    0.43
                                                                                                                                                                                                                                     Replication                      19   1            0    NA                
                                                                                                                                                                                                                                     Combined                         75   4            0    0.01617           
  22                                                   VCR    10   rs148377922   114,901,092   *TCF7L2*                                                  G/A   Intron 5                                                  Resistant   Screening                        48   7            1    0.03119   −0.10   0.40
                                                                                                                                                                                                                                     Replication                      18   2            0    0.20720           
                                                                                                                                                                                                                                     Combined                         66   9            1    0.01649           
  23                                                   CPM    8    rs17652171    113,662,583   *CSMD3*                                                   A/C   Intron 18                                                 Resistant   Screening                        52   7            0    0.04256   −0.15   0.21
                                                                                                                                                                                                                                     Replication                      18   2            0    0.37710           
                                                                                                                                                                                                                                     Combined                         70   9            0    0.01711           
  24                                                   MMC    18   --            22,642,748    *ZNF521*                                                  A/C   Intron 7                                                  Resistant   Screening                        51   8            0    0.04618   0.07    0.58
                                                                                                                                                                                                                                     Replication                      19   1            0    NA                
                                                                                                                                                                                                                                     Combined                         70   9            0    0.01743           
  25                                                   ADR    11   rs10895289    102,199,611   *BIRC3*                                                   A/T   Intron 1                                                  Sensitive   Screening                        51   6            0    0.01991   −0.05   0.86
                                                                                                                                                                                                                                     Replication                      19   1            0    NA                
                                                                                                                                                                                                                                     Combined                         70   7            0    0.01977           
  26                                                   MMC    2    rs61749494    60,689,441    *BCL11A*                                                  T/C   Exon 4                                                    Sensitive   Screening                        46   13           0    0.03616   0.07    0.84
                                                                                                                                                               (E202E)                                                               Replication                      16   3            1    0.21878           
                                                                                                                                                                                                                                     Combined                         62   16           1    0.01994           
  27                                                   VCR    13   rs2491231     28,610,183    *FLT3*                                                    A/G   Intron 10                                                 Resistant   Screening                        14   13           29   0.04949   −0.25   0.12
                                                                                                                                                                                                                                     Replication                      3    4            13   0.19167           
                                                                                                                                                                                                                                     Combined                         17   17           42   0.02057           
  28                                                   5FU    14   rs67737119    95,591,070    *DICER1*                                                  G/A   Intron 8                                                  Resistant   Screening                        22   14           20   0.02660   −0.02   0.85
                                                                                                                                                                                                                                     Replication                      9    5            6    0.61376           
                                                                                                                                                                                                                                     Combined                         31   19           26   0.02387           
  29                                                   VCR    6    rs8192585     32,188,823    *NOTCH4*                                                  G/A   Exon 4      Benign                            Tolerated   Sensitive   Screening                        51   5            0    0.04130   0.51    0.38
                                                                                                                                                               (S244L)     (0.002)                           (0.84)                  Replication                      18   2            0    0.34416           
                                                                                                                                                                                                                                     Combined                         69   7            0    0.02414           
  30                                                   5FU    1    rs1539243     206,647,787   *IKBKE*                                                   T/C   Exon 4                                                    Resistant   Screening                        2    3            51   0.03643   0.05    0.79
                                                                                                                                                               (I67I)                                                                Replication                      0    1            19   NA                
                                                                                                                                                                                                                                     Combined                         2    4            70   0.02733           
  31                                                   ADR    17   rs2735611     8,048,283     *PER1*                                                    G/A   Exon 18                                                   Resistant   Screening                        38   17           2    0.03587   −0.13   0.53
                                                                                                                                                               (G749G)                                                               Replication                      12   7            1    0.84700           
                                                                                                                                                                                                                                     Combined                         50   24           3    0.02888           
  32                                                   DDP    1    rs12037217    85,742,023    *BCL10*                                                   C/A   Exon 1      Benign                            Tolerated   Resistant   Screening                        53   4            0    0.03770   −0.27   0.73
                                                                                                                                                               (A5S)       (0.000)                           (0.10)                  Replication                      18   2            0    0.44969           
                                                                                                                                                                                                                                     Combined                         71   6            0    0.02953           
  33                                                   5FU    18   --            22,642,744    *ZNF521*                                                  A/G   Intron 7                                                  Resistant   Screening                        32   24           0    0.03429   −0.39   0.002
                                                                                                                                                                                                                                     Replication                      13   7            0    0.52596           
                                                                                                                                                                                                                                     Combined                         45   31           0    0.03358           
  34                                                   CPM    1    rs139822181   144,863,320   *PDE4DIP*                                                 T/C   Exon 37     Probably                          Damaging    Sensitive   Screening                        50   9            0    0.04988   0.11    0.37
                                                                                                                                                               (K2028R)    damaging                          (−0.02)                 Replication                      19   1            0    NA                
                                                                                                                                                                           (−0.998)                                                  Combined                         69   10           0    0.03433           
  35                                                   ADR    20   rs62206933    31,023,500    *ASXL1*                                                   C/T   Exon 13                                                   Resistant   Screening                        51   6            0    0.04955   −0.04   0.84
                                                                                                                                                               (H995H)                                                               Replication                      18   2            0    0.48819           
                                                                                                                                                                                                                                     Combined                         69   8            0    0.03538           

5FU, 5-fluorouracil; ACNU, nimustine; ADR, adriamycin; CPM, cyclophosphamide; DDP, cisplatin; MMC, mitomycin C; MTX, methotrexate; VCR, vincristine; VLB, vinblastine; Chr, chromosome; SNP ID, rs ID from the NCBI database of genetic variation (dbSNP). '−', this variant is not identified in dbSNP; Ref., reference; NA, not available

variant allele was suggested to cause multidrug sensitive (ACNU, MMC, VLB and ADR)

variant allele was suggested to cause multidrug sensitive (VCR and CPM)

expression r: Pearson correlation coefficient (r) had been calculated to estimate positive (sensitive) or negative (resistant) correlation between the gene expression level and sensitivity to each anticancer drug

expression P-value, P-value of Pearson correlation coefficient.
